Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Multiple Myeloma
 More »

  • AbbVie Expands Galapagos Collaboration to Include Crohn's Disease
    ... include hepatitis C, rheumatoid arthritis, psoriasis, multiple sclerosis, Alzheimer's disease, Parkinson's disease, axial spondyloarthritis, multiple myeloma, and endometriosis. ...
    5-17-2013
  • Pharma Touting Phase II/III Wins in Run-Up to ASCO
    ... Further, the firm will also present Phase II safety and efficacy results on elotuzumab plus lenalidomide and low-dose dexamethasone in patients with relapsed multiple myeloma, ...
    5-16-2013
  • Companion Diagnostics: 52 Pick-Up
    ... Leukemia, lymphoma, and myeloma specialists at Memorial Sloan-Kettering will provide ... assay-development platform to identify multiple DNA and RNA biomarkers: "Our early focus ...
    5-9-2013
  • Top 20 Best-Selling Drugs Approved and Launched During 2012
    ... 2012 sales: $64 million Marketer(s): Onyx Pharmaceuticals Indication(s): Multiple myeloma in patients who have received at least two prior therapies, including treatment ...
    4-4-2013
  • Scaling Up Peptide Drugs
    Kyprolis(tm) (carfilzomib, Onyx Pharmaceuticals) a proteasome inhibitor to treat multiple myeloma; Gattex (teduglutide, NPS Pharmaceuticals) to treat adults with short bowel ...
    4-1-2013
  • Myeloma Collaboration Unites Janssen, U.K. Institutions
    of Cancer Research (ICR) in London will collaborate with Johnson & Johnson unit Janssen Biotech on research they hope will result in a potential new multiple myeloma drug. ...
    3-21-2013
  • Spectrum to Develop Ligand's PG-Free Melphalan
    worldwide license to develop Captisol-enabled melphalan, a new intravenous formulation of the chemotherapy drug being investigated for multiple myeloma transplant patients. ...
    3-14-2013
  • Presage, Celgene Put Heads Together to Find New Cancer Drug Combos
    application to market Pomalyst (pomalidomide) for relapsed and refractory multiple myeloma (MM) patients who did not respond to treatment within 60 days of completion of ...
    3-5-2013
  • Developing a Cancer-Specific Microarray
    targeting the four common hematological cancers: chronic lymphocytic leukemia, multiple myeloma, myeloproliferative neoplasms, and myelodysplastic syndrome. "The use of ...
    2-26-2013
  • FDA Blocks Novo, Boosts Celgene
    ... Celgene Wins Pomalyst OK Celgene said the agency approved the company's application to market the Pomalyst (pomalidomide) for relapsed and refractory multiple myeloma (MM) patients ...
    2-11-2013
  • Drug Repurposing Rekindles Promise
    ... A major triumph for repurposing was the use of thalidomide to treat the blood cancer multiple myeloma. Thalidomide was originally developed as a hypnotic in the 1950s and taken off ...
    1-25-2013
  • NeoStem Subsidiary Signs Manufacturing Services Deal with Adaptimmune
    Last month Adaptimmune reported preliminary results from an early phase clinical study using patients' own T cells that have been genetically altered to attack multiple myeloma ...
    1-16-2013
  • AbbVie Spins Off from Abbott
    sclerosis, Alzheimer's disease, Parkinson's disease, spondyloarthropathies, multiple myeloma, and endometriosis. "AbbVie launches with an outstanding portfolio, a solid ...
    1-2-2013
  • The New Economics of Orphan Diseases
    ... Growth rates vary by category. Ovarian cancer and multiple myeloma markets are expected to grow modestly because of major patent expirations. In contrast, acute myeloid leukemia ...
    1-1-2013
  • GEN Reports on Growing Interest in Antibody-Drug Conjugates
    A number of companies are already in Phase I development and many others are carrying out preclinical studies. For example, Immunomedics has a Phase I/II trial in multiple myeloma ...
    12-10-2012
  • More »

    Journal Articles

  • Early Surgical Laser-Assisted Management of Bisphosphonate-Related...
    Carlo Fornaini, Mauro Bonanini, Teore Ferri, Samir Nammour, Paolo Vescovi, Maddalena Manfredi, Elisabetta Merigo, Rebecca Guidotti, Marco Meleti, Giuseppe Pedrazzi, FORNAINI CARLO, BONANINI MAURO
    Photomedicine and Laser Surgery
    Methods: One hundred and twenty eight patients (33 males, 95 females; 52 with diagnosis of multiple myeloma, 53 of bone metastasis and 23 of osteoporosis) affected by BRONJ were ...
  • Necrotizing Soft Tissue Infection in Two Patients with Multiple...
    Samuel Sultan, Ewelina Morawa, Ruben Niesvizky, Mia Talmor, Philip S. Barie
    Surgical Infections
    Necrotizing Soft Tissue Infection in Two Patients with Multiple Myeloma Surgical Infections Abstract Background: Necrotizing soft tissue infection (NSTI) remains associated with ...
  • Proteomic Analysis of Bone Tissues of Patients with Osteonecrosis...
    Huarong Zhang, Lei Zhang, Jun Wang, Yingying Ma, Jing Zhang, Fan Mo, Weiyi Zhang, Shigui Yan, Guojing Yang
    OMICS: A Journal of Integrative Biology
    GSEA (gene set enrichment analysis) revealed that proteins overexpressed in ONFH are enriched for gene sets related to multiple myeloma and adult T-cell lymphoma (ATL), and to ...
  • Identification of Two Groups of Smoldering Multiple Myeloma Patients...
    Yuning Xiong, Kathleen A. Donovan, Michael P. Kline, Michael K. Gornet, Laurie L. Moon-tasson, Martha Q. Lacy, Angela Dispenzieri, Morie A. Gertz, Philip R. Greipp, John A. Lust
    Journal of Interferon & Cytokine Research
    Identification of Two Groups of Smoldering Multiple Myeloma Patients Who Are Either High or Low Producers of Interleukin-1 Journal of Interferon & Cytokine Research Interleukin-1ß ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll